The field is quite new, so its ultimate success at finding new drugs is still unknown.

These numbers prove once again the real power of a strong oncology franchise.

The technology is in a very early stage in general, so it may in the future provide breakthroughs but in the short-term it is certainly going to take time.

It's a frustration that these letters aren't considered public and so it's difficult to understand what the risks are.

This is still a very new area will that continue to grow. At some point, we won't differentiate between these drugs.

Roche is providing innovation. I could not care less about the hundreds of anti high-blood pressure products. This drug looks like it will literally give women a new lease of life.